ClinicalTrials.gg
CompletedNCT05414175HORIZON-HCMUpdated Jan 27, 2026Results posted

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

A Phase 3 interventional study of Mavacamten in Cardiomyopathy, Hypertrophic Obstructive, sponsored by Bristol-Myers Squibb. Completed at 20 sites in Japan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.

Enrollment
18th of 21
38 · median 75
Started
2022
with 3 others
Phase 3
6 of 21
none open now
Registered
12th of 21
by date
Lead sponsor
10 of 21
Bristol-Myers Squibb

Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 18th largest by enrollment, is one of 4 that started in 2022, is one of 6 in phase 3, and was the 12th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MYK-461

MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness, safety, and tolerability of a 30-week course of mavacamten and the long-term effects of mavacamten in Japanese participants with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

03

Conditions studied

  • Cardiomyopathy, Hypertrophic Obstructive

Keywords

  • Mavacamten
  • Obstructive Hypertrophic Cardiomyopathy (HCM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 and greater, body weight ≥ 35kg
  • Has adequate acoustic windows to enable accurate transthoracic echocardiograms (TTEs)
  • Diagnosed with obstructive hypertrophic cardiomyopathy consistent with current American College of Cardiology Foundation/American Heart Association, European Society of Cardiology, and Japanese Circulation Society guidelines
  • Has documented (LVEF) ≥60% Class II or III

Exclusion criteria

Exclusion Criteria:

  • Known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM, such as Fabry disease, amyloidosis, or Noonan syndrome with LV hypertrophy
  • History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to Screening
  • History of resuscitated sudden cardiac arrest (at any time) or known history of appropriate implantable cardioverter defibrillator (ICD) discharge for life-threatening ventricular arrhythmia within 6 months prior to Screening
  • Paroxysmal atrial fibrillation with atrial fibrillation present at the time of Screening.
  • Persistent or permanent atrial fibrillation not on anticoagulation for at least 4 weeks prior to Screening and/or not adequately rate controlled within 6 months prior to Screening
  • Treatment (within 14 days prior to Screening) or planned treatment during the study with cibenzoline, disopyramide or ranolazine
  • Treatment (within 14 days prior to Screening) or planned treatment during the study with a combination of beta blockers and verapamil or a combination of beta blockers and diltiazem
  • Has been successfully treated with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation [ASA]) within 6 months prior to Screening or plans to have either of these treatments during the study
  • ICD placement within 2 months prior to Screening or planned ICD placement during the study
  • Has a history or evidence of any other disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety or interfere with the study evaluation procedures, or completion
  • Prior treatment with cardiotoxic agents such as doxorubicin or similar

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Mavacamten

    Drug: Mavacamten

Interventions

  • Specified dose on specified days

    Also known as: BMS-986427, MYK-461

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Post-exercise Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30

    The post-exercise LVOT gradient was measured from echocardiograms obtained at baseline and week 30 following a study-specified exercise protocol and read by the doppler echocardiography. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment.

    Time frame: At Baseline and Week 30

Secondary outcomes

  1. Change From Baseline in Kansas City Cardiomyopathy Questionnaire 23-item Version (KCCQ-23) Clinical Summary Score (CSS) at Week 30

    The KCCQ-23 is a 23-item, self-administered questionnaire that measures the impact of a participant's cardiovascular disease or its treatment on 6 distinct domains using a 2-week recall period: symptoms/signs, physical limitation, quality of life (QoL), social limitations, self-efficacy, and symptom stability. The KCCQ 23 Clinical Summary Score (CSS) is derived from the Total Symptom Score (TSS) and the Physical Limitations (PL) score of the KCCQ 23. The CSS, TSS, and the PL score range from 0 to 100 with higher scores representing less severe symptoms and/or physical limitations. The CSS is a mean of the TSS and the PL score. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment.

    Time frame: At Baseline and Week 30

  2. Percentage of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 30

    The NYHA Functional Classification of Heart Failure (HF) assigns participants to 1 of 4 categories based on the participant's symptoms. Class I (No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea); Class II (Slight limitation of physical activity, Comfortable at rest, Ordinary physical activity results in fatigue, palpitation, dyspnea); Class III (Marked limitation of physical activity, Comfortable at rest, Less-than ordinary-activity causes fatigue, palpitation, or dyspnea) and Class IV (Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases). Improvement is defined as participant moving to lower class category from a higher one. Baseline is defined as last non-missing measurement prior to the first dose.

    Time frame: Baseline and at Week 30

  3. Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 30

    Blood samples were collected for assessing the concentration of NT-proBNP. Baseline is defined as last non-missing measurement prior to the first dose.

    Time frame: At baseline and week 30

  4. Change From Baseline in Cardiac Troponin I at Week 30

    Blood samples were collected for assessing cardiac troponins. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment.

    Time frame: At baseline and week 30

  5. Change From Baseline in Cardiac Troponin T at Week 30

    Blood samples were collected for assessing cardiac troponins. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment.

    Time frame: At baseline and week 30

07

Results

Posted Dec 4, 2024

Participant flow

Participant flow — Overall Study
MilestoneMavacamten
Started38
Intent to treat population38
Safety population38
Completed36
Not completed2
Withdrew: Withdrawal by subject1
Withdrew: Other reasons1

Outcome measures

PrimaryChange From Baseline in Post-exercise Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30

The post-exercise LVOT gradient was measured from echocardiograms obtained at baseline and week 30 following a study-specified exercise protocol and read by the doppler echocardiography. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment.

Time frame:
At Baseline and Week 30
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Post-exercise Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30
millimeters of mercury (mmHg)Mavacamten
Change From Baseline in Post-exercise Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30-60.6963 ± 31.55674
SecondaryChange From Baseline in Kansas City Cardiomyopathy Questionnaire 23-item Version (KCCQ-23) Clinical Summary Score (CSS) at Week 30

The KCCQ-23 is a 23-item, self-administered questionnaire that measures the impact of a participant's cardiovascular disease or its treatment on 6 distinct domains using a 2-week recall period: symptoms/signs, physical limitation, quality of life (QoL), social limitations, self-efficacy, and symptom stability. The KCCQ 23 Clinical Summary Score (CSS) is derived from the Total Symptom Score (TSS) and the Physical Limitations (PL) score of the KCCQ 23. The CSS, TSS, and the PL score range from 0 to 100 with higher scores representing less severe symptoms and/or physical limitations. The CSS is a mean of the TSS and the PL score. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment.

Time frame:
At Baseline and Week 30
Reported as:
Mean · Score on a Scale
Change From Baseline in Kansas City Cardiomyopathy Questionnaire 23-item Version (KCCQ-23) Clinical Summary Score (CSS) at Week 30
Score on a ScaleMavacamten
Change From Baseline in Kansas City Cardiomyopathy Questionnaire 23-item Version (KCCQ-23) Clinical Summary Score (CSS) at Week 309.766 ± 16.8588
SecondaryPercentage of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 30

The NYHA Functional Classification of Heart Failure (HF) assigns participants to 1 of 4 categories based on the participant's symptoms. Class I (No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea); Class II (Slight limitation of physical activity, Comfortable at rest, Ordinary physical activity results in fatigue, palpitation, dyspnea); Class III (Marked limitation of physical activity, Comfortable at rest, Less-than ordinary-activity causes fatigue, palpitation, or dyspnea) and Class IV (Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases). Improvement is defined as participant moving to lower class category from a higher one. Baseline is defined as last non-missing measurement prior to the first dose.

Time frame:
Baseline and at Week 30
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 30
Percentage of participantsMavacamten
Percentage of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 3063.2
SecondaryChange From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 30

Blood samples were collected for assessing the concentration of NT-proBNP. Baseline is defined as last non-missing measurement prior to the first dose.

Time frame:
At baseline and week 30
Reported as:
Median · nanogram per liter (ng/L)
Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 30
nanogram per liter (ng/L)Mavacamten
Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 30-738.0 (-3101 to 590)
SecondaryChange From Baseline in Cardiac Troponin I at Week 30

Blood samples were collected for assessing cardiac troponins. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment.

Time frame:
At baseline and week 30
Reported as:
Median · ng/L
Change From Baseline in Cardiac Troponin I at Week 30
ng/LMavacamten
Change From Baseline in Cardiac Troponin I at Week 30-10.920 (-226.42 to 0.80)
SecondaryChange From Baseline in Cardiac Troponin T at Week 30

Blood samples were collected for assessing cardiac troponins. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment.

Time frame:
At baseline and week 30
Reported as:
Median · ng/L
Change From Baseline in Cardiac Troponin T at Week 30
ng/LMavacamten
Change From Baseline in Cardiac Troponin T at Week 30-4.95 (-19.2 to 0.3)

Adverse events

Collected over All-cause mortality was measured from first dose up until approximately 66 weeks post-first dose. SAEs and Other AEs were collected from first dose till last dose plus 140 days (up to approximately 50 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mavacamten0/38 (0%)6/38 (15.8%)20/38 (52.6%)
Most frequent serious events
Most frequent serious events
EventMavacamten
Atrial fibrillationCardiac disorders1/38
Macular oedemaEye disorders1/38
CholangitisHepatobiliary disorders1/38
Cholecystitis acuteHepatobiliary disorders1/38
COVID-19Infections and infestations1/38
Colonic abscessInfections and infestations1/38
Rotator cuff syndromeMusculoskeletal and connective tissue disorders1/38
Cerebral haemorrhageNervous system disorders1/38
Most frequent other events
Showing 10 of 13
Most frequent other events
EventMavacamten
COVID-19Infections and infestations8/38
NasopharyngitisInfections and infestations6/38
Atrial fibrillationCardiac disorders3/38
PyrexiaGeneral disorders3/38
HypertensionVascular disorders3/38
PalpitationsCardiac disorders2/38
CataractEye disorders2/38
Abdominal painGastrointestinal disorders2/38
MalaiseGeneral disorders2/38
BronchitisInfections and infestations2/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)Mavacamten
Mean64.8 ± 10.95
Sex: Female, Male
Sex: Female, Male(Participants)Mavacamten
Female25
Male13
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Mavacamten
Japanese38
08

Study locations

20 sites
  • Local Institution - 0020
    Uwajima, Ehime 798-8510, Japan
  • Local Institution - 0026
    Himeji-Shi, Hyōgo 672-8044, Japan
  • Local Institution - 0016
    Kobe, Hyōgo 650-0047, Japan
  • Local Institution - 0017
    Tsukuba, Ibaraki 305-0005, Japan
  • Local Institution - 0023
    Kanazawa, Ishikawa-ken 920-8641, Japan
  • Local Institution - 0019
    Yokohama, Kanagawa 227-8501, Japan
  • Local Institution - 0015
    Nankoku-shi, Kochi 783-8505, Japan
  • Local Institution - 0028
    Tsu, Mie-ken 514-8507, Japan
  • Local Institution - 0027
    Sendai, Miyagi 980-8574, Japan
  • Local Institution - 0014
    Suita, Osaka 564-8565, Japan
  • Local Institution - 0011
    Suita-Shi, Osaka 565-0871, Japan
  • Local Institution - 0012
    Hamamatsu, Shizuoka 431-3192, Japan
  • Local Institution - 0010
    Bunkyo-Ku, Tokyo 113-0033, Japan
  • Local Institution - 0009
    Chuo-Ku, Tokyo 104-0044, Japan
  • Local Institution - 0003
    Fuchu-Shi, Tokyo 1830003, Japan
  • Local Institution - 0001
    Itabashi-Ku, Tokyo 173-0003, Japan
  • Local Institution - 0007
    Koto-Ku, Tokyo 135-0061, Japan
  • Local Institution - 0005
    Shinjuku-Ku, Tokyo 160-8582, Japan
  • Local Institution - 0013
    Shinjuku-ku, Tokyo 162-8666, Japan
  • Local Institution - 0018
    Osaka, 558-8558, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Nov 2023, 15 months.

Results were first posted in Dec 2024, 1 year after primary completion.

Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2022
First posted
Jun 10, 2022
StartActual
Aug 19, 2022
Primary completionActual
Nov 27, 2023
CompletionActual
Dec 11, 2025
Results first posted
Dec 4, 2024
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05414175
Responsible party
Sponsor
First posted
Jun 10, 2022
Start date
Aug 19, 2022
Primary completion
Nov 27, 2023
Completion
Dec 11, 2025
Results posted
Dec 4, 2024
Last update
Jan 27, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion